Pharmaceuticals company Hester Biosciences announced Q1FY26 results Revenue from operations: Rs 841.05 million compared to Rs 822.67 million during Q1FY25, change 2%. EBITDA: Rs 261.79 million compared to Rs 197.35 million during Q1FY25, change 33%. EBITDA Margin: 31% for Q1FY26. PAT: Rs 172.96 million compared to Rs 74.86 million during Q1FY25, change 131%. EPS: Rs 20.33 for Q1FY26. Animal Healthcare Division: In Q1FY26, the division recorded a 33% decline in sales, primarily due to timing delays in key government Immunisation programmes for PPR and Lumpy Skin Disease, in which Hester’s PPR and Goat Pox vaccines respectively, are widely used, have got delayed. Poultry Healthcare Division: The Poultry Healthcare Division recorded a 2% growth in Q1FY26, led by robust demand for key vaccines, particularly for Newcastle Disease and Marek’s Disease. Result PDF